- insurance
- serpina1
Protecting You while Helping Insurers Serve with Excellence
Every person carries the SerpinA1 gene, which has hundreds of possible allele variations. Some of these alleles have historically been linked to Alpha-1 Antitrypsin Deficiency (AATD), a rare and often misunderstood condition. At the time of our patent filing, only about 8,000 individuals worldwide had been identified with AATD, and the insurance industry was largely unaware of its existence.
Importantly, having a SerpinA1 allele that is not "M" does not mean a person has a disease. Yet without our safeguards, individuals risk discrimination in the insurance underwriting process.
Our Mission
Protect privacy: Ensure applicants are never required to disclose genetic information about SerpinA1 or Alpha-1 Antitrypsin Deficiency during insurance applications or medical exams.
Prevent discrimination: Stop insurers from misusing genetic data to deny coverage or raise premiums.
Empower individuals: Give people confidence to apply for all lines of insurance without fear of bias.
Our Patent
Our founder, Mark Egly, secured a U.S. patent covering the insurance application process for individuals with or without Alpha-1 Antitrypsin Deficiency. This patent:
- Defines what information insurers can and cannot request
- Blocks potentially discriminatory questions about genetic status
- Protects applicants from fraud and unfair underwriting practices
Why It Matters
For individuals: Having a unique SerpinA1 allele does not equal illness. Our protections ensure fair access to insurance.
For insurers: Actuaries have long calculated premiums without factoring in AATD. Our patented methods allow insurers to engage policyholders only after coverage is in force—sharing educational resources without underwriting discrimination.
Learn more on The Patent or Take Action.